CoChat
Sign Up
Cited by 42

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy

Ostrominski, John W., Guo, Ruby, Elliott, Perry M., Ho, Carolyn Y.·2023·JACC: Heart Failure
DOI 10.1016/j.jchf.2023.04.018
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jchf.2023.04.018

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 79

  1. Maron, 1995, Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary Artery Risk Development in (Young) Adults, Circulation, 92, 785, 10.1161/01.CIR.92.4.785 · DOI
  2. Maron, 2018, Global burden of hypertrophic cardiomyopathy, J Am Coll Cardiol HF, 6, 376
  3. Lehman, 2022, Targeting the sarcomere in inherited cardiomyopathies, Nat Rev Cardiol, 19, 353, 10.1038/s41569-022-00682-0 · DOI
  4. Marian, 2021, Molecular genetic basis of hypertrophic cardiomyopathy, Circ Res, 128, 1533, 10.1161/CIRCRESAHA.121.318346 · DOI · Paper page
  5. Harper, 2021, Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity, Nat Genet, 53, 135, 10.1038/s41588-020-00764-0 · DOI · Paper page
  6. Tadros, 2023, Large scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy, medRxiv
  7. Maron, 2003, Effect of left ventricular outflow obstruction on clinical outcome in hypertrophic cardiomyopathy, N Engl J Med, 348, 295, 10.1056/NEJMoa021332 · DOI · Paper page
  8. Elliott, 2006, Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy, Eur Heart J, 27, 1933, 10.1093/eurheartj/ehl041 · DOI
  9. Sorajja, 2009, Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study, J Am Coll Cardiol, 54, 234, 10.1016/j.jacc.2009.01.079 · DOI
  10. Ho, 2010, Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy, N Engl J Med, 363, 552, 10.1056/NEJMoa1002659 · DOI
  11. Elliott, 2014, 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284 · DOI · Paper page
  12. Ommen, 2020, 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology American Heart Association Joint Committee on Clinical Practice Guidelines, J Am Coll Cardiol, 76, e159, 10.1016/j.jacc.2020.08.045 · DOI · Paper page
  13. Maron, 2022, Management of hypertrophic cardiomyopathy: JACC State-of-the-Art Review, J Am Coll Cardiol, 79, 390, 10.1016/j.jacc.2021.11.021 · DOI
  14. Maron, 2018, Clinical course and management of hypertrophic cardiomyopathy, N Engl J Med, 379, 655, 10.1056/NEJMra1710575 · DOI · Paper page
  15. Maron, 2015, Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies, J Am Coll Cardiol, 65, 1915, 10.1016/j.jacc.2015.02.061 · DOI · Paper page
  16. Kimmelstiel, 2019, Guideline-based referral for septal reduction therapy in obstructive hypertrophic cardiomyopathy is associated with excellent clinical outcomes, Circ Cardiovasc Interv, 12, 10.1161/CIRCINTERVENTIONS.118.007673 · DOI
  17. Ommen, 2005, Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 46, 470, 10.1016/j.jacc.2005.02.090 · DOI
  18. Sorajja, 2022, Alcohol septal ablation for obstructive hypertrophic cardiomyopathy, Intervent Cardiol Clin, 11, 245
  19. Holst, 2022, Impact of hospital volume on outcomes of septal myectomy for hypertrophic cardiomyopathy, Ann Thorac Surg, 114, 2131, 10.1016/j.athoracsur.2022.05.062 · DOI
  20. Kim, 2016, Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient Database, 2003-2011, JAMA Cardiol, 1, 324, 10.1001/jamacardio.2016.0252 · DOI
  21. Wells, 2018, Clinical profile of nonresponders to surgical myectomy with obstructive cardiomyopathy, Am J Med, 131, e235, 10.1016/j.amjmed.2017.12.031 · DOI
  22. Liebregts, 2015, A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy, J Am Coll Cardiol HF, 3, 896
  23. Ho, 2018, Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe), Circulation, 138, 1387, 10.1161/CIRCULATIONAHA.117.033200 · DOI · Paper page
  24. Marstrand, 2020, Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the ShaRe Registry, Circulation, 141, 1371, 10.1161/CIRCULATIONAHA.119.044366 · DOI · Paper page
  25. Cisneros, 2018, Outcomes in patients with hypertrophic cardiomyopathy awaiting heart transplantation, Circ Heart Fail, 11
  26. Chuang, 2021, Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy, J Med Chem, 64, 14142, 10.1021/acs.jmedchem.1c01290 · DOI
  27. Green, 2016, A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice, Science, 351, 617, 10.1126/science.aad3456 · DOI
  28. Day, 2022, Myosin modulators: emerging approaches for the treatment of cardiomyopathies and heart failure, J Clin Invest, 132, 10.1172/JCI148557 · DOI
  29. Heitner, 2019, Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial, Ann Intern Med, 170, 741, 10.7326/M18-3016 · DOI
  30. Ho, 2020, Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 75, 2649, 10.1016/j.jacc.2020.03.064 · DOI
  31. Olivotto, 2020, Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 396, 759, 10.1016/S0140-6736(20)31792-X · DOI · Paper page
  32. Desai, 2022, Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy, J Am Coll Cardiol, 80, 95, 10.1016/j.jacc.2022.04.048 · DOI
  33. Maron, 2023, Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 81, 34, 10.1016/j.jacc.2022.10.020 · DOI
  34. Keam, 2022, Mavacamten: first approval, Drugs, 82, 1127, 10.1007/s40265-022-01739-7 · DOI
  35. Walsh, 2017, Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples, Genet Med, 19, 192, 10.1038/gim.2016.90 · DOI
  36. Moore, 2012, Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor, Circ Res, 111, 375, 10.1161/CIRCRESAHA.110.223842 · DOI
  37. Rohde, 2018, Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin, Proc Natl Acad Sci U S A, 115, E7486, 10.1073/pnas.1720342115 · DOI
  38. Anderson, 2018, Deciphering the super relaxed state of human β-cardiac myosin and mode of action of mavacamten from myosin molecules to muscle fibers, Proc Natl Acad Sci U S A, 115, E8143, 10.1073/pnas.1809540115 · DOI
  39. Toepfer, 2020, Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy, Circulation, 141, 828, 10.1161/CIRCULATIONAHA.119.042339 · DOI
  40. Kawas, 2017, A small-molecular modulatory of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle, J Biol Chem, 292, 16571, 10.1074/jbc.M117.776815 · DOI
  41. Gollapudi, 2021, Two classes of myosin inhibitors, para-nitroblebbistatin and mavacamten, stabilize β-cardiac myosin in different structural and functional states, J Mol Biol, 433, 10.1016/j.jmb.2021.167295 · DOI
  42. Kampourakis, 2018, Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament, J Physiol, 596, 31, 10.1113/JP275050 · DOI
  43. Grillo, 2019, In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin, Xenobiotica, 49, 718, 10.1080/00498254.2018.1495856 · DOI
  44. Fordyce, 2015, Cardiovascular drug development: is it dead or just hibernating?, J Am Coll Cardiol, 65, 1567, 10.1016/j.jacc.2015.03.016 · DOI · Paper page
  45. Masri, 2022, Cardiac myosin inhibitors as a novel treatment option for obstructive hypertrophic cardiomyopathy: addressing the core of the matter, J Am Heart Assoc, 11
  46. Wheeler, 2023, Effects of mavacamten on measures of cardiopulmonary exercise testing beyond peak oxygen consumption: a secondary analysis of the EXPLORER-HCM randomized trial, JAMA Cardiol, 8, 240, 10.1001/jamacardio.2022.5099 · DOI
  47. Saberi, 2021, Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy analysis, Circulation, 143, 606, 10.1161/CIRCULATIONAHA.120.052359 · DOI · Paper page
  48. Hegde, 2021, Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 78, 2518, 10.1016/j.jacc.2021.09.1381 · DOI
  49. Desai, 2023, Dose-blinded myosin inhibition in patients with obstructive HCM referred for septal reduction therapy: outcomes through 32 weeks, Circulation, 147, 850, 10.1161/CIRCULATIONAHA.122.062534 · DOI
  50. Beinfeld, 2022, Mavacamten for hypertrophic cardiomyopathy: effectiveness and value, J Manag Care Spec Pharm, 28, 369
  51. Ommen, 2022, Cardiac myosin inhibitors for obstructive hypertrophic cardiomyopathy: where are we on the hype cycle?, J Am Coll Cardiol, 80, 109, 10.1016/j.jacc.2022.05.009 · DOI
  52. Spertus, 2021, Health status benefits of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy: results from the EXPLORER-HCM randomized clinical trial, Lancet, 397, 2467, 10.1016/S0140-6736(21)00763-7 · DOI · Paper page
  53. Maron, 2015, Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction, J Am Coll Cardiol, 66, 1307, 10.1016/j.jacc.2015.06.1333 · DOI · Paper page
  54. Habib, 2019, Markers of responsiveness to disopyramide in patients with hypertrophic cardiomyopathy, Int J Cardiol, 297, 75, 10.1016/j.ijcard.2019.09.066 · DOI
  55. Wheeler, 2023, Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy, Eur J Heart Fail, 25, 260, 10.1002/ejhf.2737 · DOI · Paper page
  56. Maurizi, 2018, Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors for lethal arrhythmic events, JAMA Cardiol, 3, 520, 10.1001/jamacardio.2018.0789 · DOI
  57. Marston, 2021, Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy, Eur Heart J, 42, 1988, 10.1093/eurheartj/ehab148 · DOI
  58. Saberi, 2021, Hypertrophic cardiomyopathy in pregnancy, Cardiol Clin, 39, 143
  59. Maron, 2016, Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 67, 1399, 10.1016/j.jacc.2016.01.023 · DOI
  60. Elliott, 2016, Hypertrophic cardiomyopathy: job done or work in progress?, J Am Coll Cardiol, 67, 1410, 10.1016/j.jacc.2016.02.009 · DOI
  61. Pelliccia, 2017, Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis, Int J Cardiol, 243, 379, 10.1016/j.ijcard.2017.06.071 · DOI · Paper page
  62. Olivotto, 2016, Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of late sodium current inhibition on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM) trial, Circ Heart Fail, 9, 10.1161/CIRCHEARTFAILURE.115.002764 · DOI
  63. Axelsson, 2015, Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial, Lancet Diabetes Endocrinol, 3, 123, 10.1016/S2213-8587(14)70241-4 · DOI
  64. Axelsson, 2016, Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial, Heart, 102, 285, 10.1136/heartjnl-2015-308343 · DOI
  65. Olivotto, 2018, Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study, Circ Heart Fail, 11, 10.1161/CIRCHEARTFAILURE.117.004124 · DOI
  66. Maron, 2018, Effect of spironolactone in myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy, Am J Med, 131, 837, 10.1016/j.amjmed.2018.02.025 · DOI
  67. Coats, 2019, Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy, JAMA Cardiol, 4, 230, 10.1001/jamacardio.2018.4847 · DOI
  68. Heinzel, 2022, The future of heart failure with preserved ejection fraction: deep phenotyping for targeted therapeutics, Herz, 47, 308, 10.1007/s00059-022-05124-8 · DOI
  69. Forrest, 2022, Genetic and phenotypic profiling of supranormal ejection fraction reveals decreased survival and underdiagnosed heart failure, Eur J Heart Fail, 24, 2118, 10.1002/ejhf.2482 · DOI
  70. Shah, 2022, Supranormal left ventricular ejection fraction, stroke volume, and cardiovascular risk: findings from population-based cohort studies, J Am Coll Cardiol HF, 10, 583
  71. Kyalwazi, 2022, Disparities in cardiovascular mortality between Black and White adults in the United States, 1999-2019, Circulation, 146, 211, 10.1161/CIRCULATIONAHA.122.060199 · DOI
  72. Maron, 2003, Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy, J Am Coll Cardiol, 41, 974, 10.1016/S0735-1097(02)02976-5 · DOI
  73. Ntusi, 2021, Associations of race and ethnicity with presentation and outcomes of hypertrophic cardiomyopathy: JACC Focus Seminar 6/9, J Am Coll Cardiol, 78, 2573, 10.1016/j.jacc.2021.10.020 · DOI
  74. Minhas, 2022, Demographic and regional trends of hypertrophic cardiomyopathy-related mortality in the United States, 1999-2019, Circ Heart Fail, 15, 10.1161/CIRCHEARTFAILURE.121.009292 · DOI
  75. Ostrominski, 2022, Cost and value in contemporary heart failure clinical guidance documents, J Am Coll Cardiol HF, 10, 1
  76. Anderson, 2014, ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2304, 10.1016/j.jacc.2014.03.016 · DOI
  77. Heidenreich, 2022, 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, J Am Coll Cardiol, 79, e263, 10.1016/j.jacc.2021.12.012 · DOI · Paper page
  78. Greene, 2021, Comparison of New York Heart Association class and patient-reported outcomes for heart failure with reduced ejection fraction, JAMA Cardiol, 6, 522, 10.1001/jamacardio.2021.0372 · DOI
  79. Lorenzini, 2020, Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers, J Am Coll Cardiol, 76, 550, 10.1016/j.jacc.2020.06.011 · DOI

Cited by

Sorted by citations

See all 42

Metadata

Authors
Ostrominski, J. W., Guo, R., Elliott, P. M., & Ho, C. Y.
Venue
JACC: Heart Failure
Publisher
Elsevier BV
Published
2023-07
Volume
11
Issue
7
Pages
735-748
ISSN
2213-1779
DOI
10.1016/j.jchf.2023.04.018
Cited by
42
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy. https://app.cochat.ai/papers/10.1016/j.jchf.2023.04.018
The paper
Ostrominski, J. W., Guo, R., Elliott, P. M., & Ho, C. Y. (2023). Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy. JACC: Heart Failure. https://doi.org/10.1016/j.jchf.2023.04.018